- Accidental discovery: mRNAVaccination helps detect cancerous tumors
- Hope in the fight against Krebs: Is there a universal vaccination coming soon?
- The first laboratory tests on animals were extremely successful
Scientists of the University of Florida have accidentally discovered a promising weapon against cancer. An experimental mRNA vaccine that was not originally developed to fight cancer triggers exceptionally strong immune reactions. The researchers found that the vaccine makes even stubborn tumors vulnerable that have previously barely responded to modern treatment methods.
More health news here:
The discovery was published in the scientific journal “Nature Biomedical Engineering” published. The vaccine works particularly effectively in combination with already approved cancer drugs, the so-called checkpoint inhibitors. They help the immune system better recognize and fight cancer cells by turning off certain “brakes” (checkpoints) that otherwise hold the immune system back.
In animal experiments, this double strategy produced a particularly powerful defense reaction in the body. Even tumors that had previously successfully resisted therapies could be combated in this way.
Double whammy against resistant tumors
Table of Contents
The mRNA vaccine uses tiny fat particles as a means of transport to deliver its message into the body. Once there, it puts the immune system on high alert. The researchers observed that this intensive activation even makes cancer cells visible that normally successfully hide from the body’s own defenses.
The combination with checkpoint inhibitors – drugs that are already used in cancer therapy – proved to be particularly effective. The vaccine wakes up the immune system while the checkpoint inhibitors release the brakes. This strategy breaks the resistance of tumors that no longer respond to conventional immunotherapies.
Immune cells act like a domino effect
The animal experiments produced impressive results. Researchers took immune cells from treated animals and transferred them to mice with completely different, usually therapy-resistant tumors. The amazing thing: The immune cells also successfully fought these types of cancer – but only if certain signaling pathways remained intact.
Scientists refer to this phenomenon as “epitope spreading”. The immune system learns to identify more and more characteristic features of cancer cells. A more comprehensive and stable defense against various types of tumors develops.
In dogs with aggressive brain tumors, treatment was without serious side effects. The organ functions remained stable and the blood values showed no abnormalities. These results make the researchers optimistic about the planned tests on humans.
Interferon signals as the key to success
The researchers identified a crucial factor for the effectiveness of the vaccine: early interferon signals. These endogenous messenger substances act as an alarm system and make tumors recognizable to the immune system. If the scientists specifically blocked these signaling pathways, the therapy failed completely.
In control groups without a functioning interferon response, treatment was not successful. “The resistance to immunotherapy can be explained by a lack of IFN-I responses,” explains study leader Elias Sayour. Activating these early warning signals is crucial for uncovering hidden cancer cells.
The research team emphasizes in the study: “Epitope spreading can be induced by the initiation of a strong IFN-I response, enabling broader and more effective immunity against tumor antigens.” Without these molecular alarm bells, the immune system remains blind to the threat.
Universal cancer weapon in sight
The promising animal experiments pave the way for human testing. Clinical studies are intended to show whether the mRNA vaccine also achieves the hoped-for success in cancer patients. The researchers are already planning the next steps towards market launch.
“These vaccines could be commercialized as universal cancer vaccines to sensitize the immune system against a patient’s individual tumor,” explains Elias Sayour. The approach promises broad applicability against various types of cancer.
The accidental discovery could prove to be a breakthrough in cancer medicine. A strong alarm signal from the immune system may be enough to unmask even well-camouflaged tumors. However, before approval, the scientists still have to prove that their findings from the laboratory also apply in clinical practice.
Here you can YouTube-Watch video.
Those:
- Qdaisat, S., Wummer, B., Stover, B. D., Zhang, D., McGuiness, J., Weidert, F., … & Sayour, E. J. (2025). Sensitization of tumours to immunotherapy by boosting early type-I interferon responses enables epitope spreading. Nature Biomedical Engineering, 1-16.
Follow News.de already at WhatsApp, Facebook, Twitter, Pinterest and YouTube? Here you will find hot news, current videos and a direct line to the editorial team.
ife/stg/mlk/news.de
date:2026-02-10 06:48:00